Stoke Therapeutics Inc (NASDAQ: STOK ) on Monday posted mixed results for the second quarter .
The company reported quarterly losses of 93 cents per share which missed the analyst consensus estimate of losses of 80 cents per share. The company reported quarterly sales of $9.325 million which beat the analyst consensus estimate of $6.044 million.
Stoke Therapeutics shares closed at $29.56 on Monday.
These analysts made changes to their price targets on Stoke Therapeutics following earnings announcement.
Canaccord Genuity analyst Sumant Kulkarni maintained the stock with a Buy and lowered the price target from $60 to $58. Wedbush analyst Laura Chico maintained the stock with an Outperform rating and raised the price target from $38 to $40.Considering buying STOK stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Markets Trading Ideas News Price Target Earnings PT Changes